Article
JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
British journal of haematology - 1 Aug 2010
Oku Seido, Takenaka Katsuto, Kuriyama Takuro, Shide Kotaro, Kumano Takashi, Kikushige Yoshikane, Urata Shingo, Yamauchi Takuji, Iwamoto Chika, Shimoda Haruko K, Miyamoto Toshihiro, Nagafuji Koji, Kishimoto Junji, Shimoda Kazuya, Akashi Koichi
Abstract excerpt
The acquired JAK2 V617F mutation is observed in the majority of patients with BCR-ABL1 negative chronic myeloproliferative neoplasms (MPN). BCR-ABL1 negative MPN displays myeloproliferation with an elevated leucocyte alkaline phosphatase (LAP) activity, a neutrophil activation marker. We tried to separate the downstream signalling of JAK2 V617F to stimulate myeloproliferation and LAP activity. NB4, a myeloid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.